Abstracts (HTML) List of Authors

Tardelli, M

Absence of BSEP (ABCB11) protects MDR2 (ABCB4) KO mice from cholestatic liver and bile duct injury through modulating the inflammatory signaling

Tevini, J

The natural course of anti-mitochondrial antibody positive subjects is similar in confirmatory immunoblot-M2 positive and negative subjects

Texler, B

Nampt Inhibition, ein neuer Therapieansatz bei akuter graft-versus-host-disease.
Selektive Effekte des JAK-Inhibitors Tofacitinib auf die T-Zell Immunität

Tikhonov, I

Pregnancy Outcomes in Women with Psoriasis, Psoriatic Arthritis, Crohn’s Disease, and Ulcerative Colitis Treated with Ustekinumab

Tilg, H

Gastric banding-associated weight loss diminishes hepatic Tsukushi expression
The PNPLA3 G-allele is common in patients with HCC but does not affect tumor characteristics and tumor biology
Neurodegenerative patterns in Wilson disease with hepatic or neurological manifestation assessed by morphometric magnetic resonance imaging
Nampt Inhibition, ein neuer Therapieansatz bei akuter graft-versus-host-disease.
Selektive Effekte des JAK-Inhibitors Tofacitinib auf die T-Zell Immunität
Der NAD+ salvage pathway in NK-Zellen bei intestinaler Inflammation
Penetrance, cancer incidence and survival of hemochromatosis in a long-term follow-up and epidemiological modeling study
Personalisierte Ernährungsmedizin am Beispiel einer Patientin mit Propionazidämie

Tillinger, W

Endoskopischer Verschluss einer Anastomosendehiszenz nach Hemikolektomie mit dem OverStitch™ Endoscopic Suturing System

Tobiasch, M

DAA therapy for chronic hepatitis c infection: risk factors for nonadherence and relapse

Tole, S

ASSOCIATION BETWEEN HISTOLOGICAL INDICES AND ULCERATIVE COLITIS ACTIVITY MEASURES AMONG PATIENTS IN THE HICKORY (ETROLIZUMAB) OPEN-LABEL INDUCTION (OLI) COHORT
ETROLIZUMAB IMPROVED ENDOSCOPIC SCORE, PATIENT REPORTED OUTCOMES, AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE UC WHO HAD FAILED TNF ANTAGONIST THERAPY: THE HICKORY OPEN-LABEL INDUCTION (OLI) COHORT

Traub, J

Sarcopenia and liver cirrhosis- Comparison of the European Working group on Sarcopenia criteria 2010 and 2019

Trauner, M

The impact of novel systemic treatment options on the outcome of patients with hepatocellular carcinoma
Predictors of response to immunotherapy in patients with hepatocellular carcinoma - a retrospective single-center experience
Regorafenib dosing in patients with advanced hepatocellular carcinoma (HCC) - a retrospective real-world experience
Absence of BSEP (ABCB11) protects MDR2 (ABCB4) KO mice from cholestatic liver and bile duct injury through modulating the inflammatory signaling
Inflammation promotes liver fibrogenesis in humans with advanced chronic liver disease
Assessment of coagulopathy by rotational thromboelastometry in patients with cirrhosis and portal hypertension
Impact of lesion phenotype on colorectal cancer mortality and overall mortality: insights from a nationwide screening colonoscopy program
Use of human albumin in a large “real-life” single-center cohort of patients with decompensated advanced chronic liver disease
Incidence and outcome of acute-on-chronic liver failure in a large retrospective single-center cohort
Features of the portal hypertensive syndrome in patients with advanced PBC
Durable Response in the Markers of Cholestasis Through 5 Years of Open-Label Extension Study of Obeticholic Acid in Primary Biliary Cholangitis
Impact of genetic variants on regression of portal hypertension and clinical outcomes in ACLD patients after SVR
Vitamin A deficiency is associated with disease severity and portal hypertension in patients with advanced chronic liver disease
Humoral biomarkers of hemodynamic derangement in distinct stages of portal hypertension
Beta blocker therapy seems to reduce systemic inflammation in cirrhotic patients with portal hypertension - a paired HVPG study
Non-invasive risk stratification by VCTE and VITRO after HCV eradication
Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsy

Tschoner, A

Personalisierte Ernährungsmedizin am Beispiel einer Patientin mit Propionazidämie

Turon, F

SVR to DAA does not affect the risk of portal vein thrombosis in patients with advanced chronic liver disease

Tyrrell, H

ETROLIZUMAB IMPROVED ENDOSCOPIC SCORE, PATIENT REPORTED OUTCOMES, AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE UC WHO HAD FAILED TNF ANTAGONIST THERAPY: THE HICKORY OPEN-LABEL INDUCTION (OLI) COHORT